Home>Topics>Companies>AstraZeneca

AstraZeneca

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Advaxis and MedImmune team up in cancer immunotherapy

    Headlines

    Tue, 22 Jul 2014

    Advaxis (NASDAQ: ADXS ) and AstraZeneca 's (NYSE: AZN ) MedImmune establish a clinical trial collaboration to evaluate the safety and efficacy of MedImmune's investigational

  2. AstraZeneca widens cancer immunotherapy net with Advaxis trial

    Headlines

    Tue, 22 Jul 2014

    LONDON, July 22 (Reuters) - AstraZeneca is casting its net wider in the hot cancer immunotherapy field through a clinical trial collaboration with U.S. biotech firm Advaxis that will test drugs from both companies in combination.

  3. Attractive tax inversion targets remain, analysts say

    Headlines

    Mon, 21 Jul 2014

    NYSE: SYK ) has been mentioned as a potential suitor for Smith& Nephew. Pfizer (NYSE: PFE ) may make another run at AstraZeneca (NYSE: AZN ) after the end of the cool-off period. Post your comment!

  4. CORRECTED-UPDATE 1-Shire, AbbVie to announce $53 bln merger by Friday -sources

    Headlines

    Thu, 17 Jul 2014

    (Corrects paragraph 7 to show failed bid for AstraZeneca happened in May not June))

  5. CORRECTED-Shire, AbbVie to announce $53 billion merger by Friday -sources

    Headlines

    Thu, 17 Jul 2014

    (Corrects 6th paragraph to show Pfizer's failed bid for AstraZeneca happened in May not June)

  6. Xalkori: Pfizer's Lung Cancer Drug Might Get A Future Boost In Sales

    Headlines

    Thu, 17 Jul 2014

    secret that Pfizer (NYSE: PFE ) has had a rocky first half this year. The difficulties around its attempt to acquire AstraZeneca (NYSE: AZN ) were compounded by Q1 sales that missed market expectations by 9 percent. As it had announced last October

  7. Medtronic Not Sticking Around To Rearrange Chairs On The Titanic

    Headlines

    Mon, 14 Jul 2014

    Considering Walgreen (NYSE: WAG ) and its plans to move to Switzerland , Pfizer's (NYSE: PFE ) failed bid for UK-based AstraZeneca (NYSE: AZN ), and now Medtronic's (NYSE: MDT ) acquisition of Ireland-based Covidien (NYSE: COV ), it's

  8. The Friday Five

    Video Reports

    Fri, 11 Jul 2014

    t going to really reap those benefits very much. We saw [TICKER:PFE] Pfizer walk away from that [TICKER:AZN] AstraZeneca deal because of valuation concerns. I think AbbVie will have to be somewhat disciplined, to not keep chasing this forever

    Astrazeneca found at 4:56

    reap those benefits very much. We saw [TICKER:PFE] Pfizer walk away from that [TICKER:AZN] AstraZeneca deal because of valuation concerns. I think AbbVie will have to be somewhat disciplined, to not keep chasing this forever. These tax
  9. Time To Take Profits In Novartis And AstraZeneca ?

    Headlines

    Mon, 7 Jul 2014

    followed our recommendation to buy Novartis ( NVS ) and AstraZeneca ( AZN ), have done very well indeed. Novartis is up ..... dividend of $2.53 last year and $2.71 this year. AstraZeneca has done even better, up by 56% (from $48.24 to

  10. Briefly On Pfizer: It's Time To Buy

    Headlines

    Thu, 3 Jul 2014

    having another go at merging with AstraZeneca ( AZN ), I was skeptical that ..... outcome to the one in January. AstraZeneca 's quick rejection following Pfizer ..... Pfizer had made their offer, before AstraZeneca started a charm offensive to convince

« Prev12345Next »
Content Partners